lurasidone (BioDeep_00000666866)
代谢物信息卡片
lurasidone
化学式: C28H36N4O2S (492.2558836)
中文名称: 鲁拉西酮
谱图信息:
最多检出来源 () 0%
Reviewed
Last reviewed on 2024-09-14.
Cite this Page
lurasidone. BioDeep Database v3. PANOMIX ltd, a top metabolomics service provider from China.
https://query.biodeep.cn/s/lurasidone (retrieved
2024-11-22) (BioDeep RN: BioDeep_00000666866). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
分子结构信息
SMILES: C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
InChI: InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
描述信息
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AE - Indole derivatives
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist
C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:70735
- PubChem: 213046
- DrugBank: DB08815
- ChEMBL: CHEMBL1237021
- MeSH: Lurasidone Hydrochloride
- CAS: 367514-87-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Wenwen Zhuang, Seo-Yeong Mun, Minju Park, Junsu Jeong, Hongzoo Park, Sunghun Na, Se Jin Lee, Won-Kyo Jung, Il-Whan Choi, Hongliang Li, Won Sun Park. Lurasidone blocks the voltage-gated potassium channels of coronary arterial smooth muscle cells.
European journal of pharmacology.
2023 Oct; 957(?):176005. doi:
10.1016/j.ejphar.2023.176005. [PMID: 37611842] - Itaru Miura, Sho Horikoshi, Mizue Ichinose, Yuhei Suzuki, Kenya Watanabe. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.
Drug design, development and therapy.
2023; 17(?):3023-3031. doi:
10.2147/dddt.s366769. [PMID: 37789971] - Catalina Montiel, Rebecca L Newmark, Crystal T Clark. Perinatal use of lurasidone for the treatment of bipolar disorder.
Experimental and clinical psychopharmacology.
2022 Apr; 30(2):249-252. doi:
10.1037/pha0000509. [PMID: 34291994] - Kouji Fukuyama, Eishi Motomura, Takashi Shiroyama, Motohiro Okada. Impact of 5-HT7 receptor inverse agonism of lurasidone on monoaminergic tripartite synaptic transmission and pathophysiology of lower risk of weight gain.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Apr; 148(?):112750. doi:
10.1016/j.biopha.2022.112750. [PMID: 35219120] - Tahlia R Meola, Paul Joyce, Anthony Wignall, Kristen E Bremmell, Clive A Prestidge. Harnessing the potential of nanostructured formulations to mimic the food effect of lurasidone.
International journal of pharmaceutics.
2021 Oct; 608(?):121098. doi:
10.1016/j.ijpharm.2021.121098. [PMID: 34534629] - Mario Milani, Manuela Donalisio, Rafaela Milan Bonotto, Edoardo Schneider, Irene Arduino, Francesco Boni, David Lembo, Alessandro Marcello, Eloise Mastrangelo. Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
Antiviral research.
2021 05; 189(?):105055. doi:
10.1016/j.antiviral.2021.105055. [PMID: 33713730] - Motohiro Okada, Ryusuke Matsumoto, Yoshimasa Yamamoto, Kouji Fukuyama. Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor.
International journal of molecular sciences.
2021 Jan; 22(3):. doi:
10.3390/ijms22031351. [PMID: 33572981] - Monalisa Jena, Archana Mishra, Biswa Ranjan Mishra, Santanu Nath, Rituparna Maiti. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.
Psychopharmacology.
2020 Nov; 237(11):3471-3480. doi:
10.1007/s00213-020-05628-3. [PMID: 32740676] - Mitali H Patel, Krutika K Sawant. Self microemulsifying drug delivery system of lurasidone hydrochloride for enhanced oral bioavailability by lymphatic targeting: In vitro, Caco-2 cell line and in vivo evaluation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2019 Oct; 138(?):105027. doi:
10.1016/j.ejps.2019.105027. [PMID: 31377133] - Imrana Jazuli, Annu, Bushra Nabi, Thasleem Moolakkadath, Tausif Alam, Sanjula Baboota, Javed Ali. Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies.
Journal of pharmaceutical sciences.
2019 09; 108(9):3082-3090. doi:
10.1016/j.xphs.2019.05.001. [PMID: 31077685] - Mitali H Patel, Veenu P Mundada, Krutika K Sawant. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization, in vitro characterization, cell line studies and in vivo efficacy in schizophrenia.
Drug development and industrial pharmacy.
2019 Aug; 45(8):1242-1257. doi:
10.1080/03639045.2019.1593434. [PMID: 30880488] - Monalisa Jena, Rajeev Ranjan, Biswa Ranjan Mishra, Archana Mishra, Santanu Nath, Pallabi Sahu, Bikash Ranjan Meher, Anand Srinivasan, Rituparna Maiti. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial.
Journal of psychiatric research.
2019 05; 112(?):1-6. doi:
10.1016/j.jpsychires.2019.02.007. [PMID: 30782512] - Charles L Raison, Andrei Pikalov, Cynthia Siu, Joyce Tsai, Kenneth Koblan, Antony Loebel. C-reactive protein and response to lurasidone in patients with bipolar depression.
Brain, behavior, and immunity.
2018 10; 73(?):717-724. doi:
10.1016/j.bbi.2018.08.009. [PMID: 30102967] - Chaoying Hu, Yijun Wang, Rong Song, Chen Yu, Xiaoyan Luo, Jingying Jia. Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects.
Clinical drug investigation.
2017 Sep; 37(9):861-871. doi:
10.1007/s40261-017-0546-8. [PMID: 28695535] - Mauricio Tohen, Daisy Ng-Mak, Krithika Rajagopalan, Rachel Halpern, Chien-Chia Chuang, Antony Loebel. Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.
The primary care companion for CNS disorders.
2017 Jun; 19(3):. doi:
10.4088/pcc.16m02066. [PMID: 28590601] - William M Greenberg, Leslie Citrome. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.
Clinical pharmacokinetics.
2017 05; 56(5):493-503. doi:
10.1007/s40262-016-0465-5. [PMID: 27722855] - Shuai Qian, Shanshan Wang, Zhen Li, Xiaojie Wang, Di Ma, Shujun Liang, Yuan Gao, Jianjun Zhang, Yuanfeng Wei. Charge-assisted bond N+H mediates the gelation of amorphous lurasidone hydrochloride during dissolution.
International journal of pharmaceutics.
2017 Feb; 518(1-2):335-341. doi:
10.1016/j.ijpharm.2016.12.059. [PMID: 28043915] - Mahitej Yadav Katteboina, Nageswara Rao Pilli, Ramesh Mullangi, Raghunadha Reddy Seelam, Shobha Rani Satla. LC-MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study.
Biomedical chromatography : BMC.
2016 Jul; 30(7):1065-1074. doi:
10.1002/bmc.3651. [PMID: 26577488] - Mark Naccarato, Elise Hall, Alan Wai, Mario Ostrowski, Adriana Carvalhal. A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy.
Antiviral therapy.
2016; 21(8):735-738. doi:
10.3851/imp3059. [PMID: 27328703] - Rajiv Tandon, Josephine Cucchiaro, Debra Phillips, David Hernandez, Yongcai Mao, Andrei Pikalov, Antony Loebel. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
Journal of psychopharmacology (Oxford, England).
2016 Jan; 30(1):69-77. doi:
10.1177/0269881115620460. [PMID: 26645209] - ". Lurasidone for schizophrenia.
Drug and therapeutics bulletin.
2015 Mar; 53(3):30-2. doi:
10.1136/dtb.2015.3.0313. [PMID: 25765597] - Terence A Ketter, Po W Wang, Shefali Miller. Bipolar therapeutics update 2014: A tale of 3 treatments.
The Journal of clinical psychiatry.
2015 Jan; 76(1):69-70. doi:
10.4088/jcp.14ac09649. [PMID: 25650673] - Yu-Yuan Chiu, Larry Ereshefsky, Sheldon H Preskorn, Nagaraju Poola, Antony Loebel. Lurasidone drug-drug interaction studies: a comprehensive review.
Drug metabolism and drug interactions.
2014; 29(3):191-202. doi:
10.1515/dmdi-2014-0005. [PMID: 24825095] - Frank I Tarazi, Marco A Riva. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
Expert opinion on drug discovery.
2013 Oct; 8(10):1297-307. doi:
10.1517/17460441.2013.815163. [PMID: 23837554] - Sheldon Preskorn, Larry Ereshefsky, Yu-Yuan Chiu, Nagaraju Poola, Antony Loebel. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies.
Human psychopharmacology.
2013 Sep; 28(5):495-505. doi:
10.1002/hup.2338. [PMID: 24014143] - Dean F Wong, Hiroto Kuwabara, James Robert Brašić, Thomas Stock, Atul Maini, Emily G Gean, Antony Loebel. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects.
Psychopharmacology.
2013 Sep; 229(2):245-52. doi:
10.1007/s00213-013-3103-z. [PMID: 23649882] - Alessia Luoni, Sjoerd Hulsken, Greta Cazzaniga, Giorgio Racagni, Judith R Homberg, Marco A Riva. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats.
The international journal of neuropsychopharmacology.
2013 Jul; 16(6):1319-30. doi:
10.1017/s1461145712001332. [PMID: 23164505] - Stephen M Stahl, Josephine Cucchiaro, Doreen Simonelli, Jay Hsu, Andrei Pikalov, Antony Loebel. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
The Journal of clinical psychiatry.
2013 May; 74(5):507-15. doi:
10.4088/jcp.12m08084. [PMID: 23541189] - Shunsuke Nakazawa, Chihiro Yokoyama, Naohiro Nishimura, Tomoko Horisawa, Akihiro Kawasaki, Hiroshi Mizuma, Hisashi Doi, Hirotaka Onoe. Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.
Psychopharmacology.
2013 Jan; 225(2):329-39. doi:
10.1007/s00213-012-2815-9. [PMID: 22868411] - William V Bobo. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Expert review of clinical pharmacology.
2013 Jan; 6(1):61-91. doi:
10.1586/ecp.12.70. [PMID: 23272794] - Marc De Hert, Weiping Yu, Johan Detraux, Kim Sweers, Ruud van Winkel, Christoph U Correll. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
CNS drugs.
2012 Sep; 26(9):733-59. doi:
10.2165/11634500-000000000-00000. [PMID: 22900950] - Shambria F Nolan, Marian W Roman. Lurasidone (latuda®): an atypical antipsychotic.
Issues in mental health nursing.
2012 May; 33(5):342-3. doi:
10.3109/01612840.2012.669025. [PMID: 22545643] - Tae-Sung Koo, Soo-Jin Kim, Jongjoo Lee, Dong-Jin Ha, Myoungki Baek, Hongsik Moon. Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry.
Biomedical chromatography : BMC.
2011 Dec; 25(12):1389-94. doi:
10.1002/bmc.1625. [PMID: 21387355] - Kyeong-Ryoon Lee, Yoon-Jee Chae, Tae-Sung Koo. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2011 Dec; 41(12):1100-7. doi:
10.3109/00498254.2011.603388. [PMID: 21838595] - R T Owen. Lurasidone: a new treatment option for schizophrenia.
Drugs of today (Barcelona, Spain : 1998).
2011 Nov; 47(11):807-16. doi:
10.1358/dot.2011.47.11.1708832. [PMID: 22146224]